Beta-Adrenergic Modulation of Drug Cue Reactivity
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age21-60
SponsorUniversity of Oklahoma
About this trial
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
Eligibility criteria
Qualifiers
Generally healthy
Age 21-60
Right-handed using a three-item scale
Daily smoker of ≥ 5 cigarettes/day delivering 0.5 mg nicotine (FTC)
Disqualifiers
Inability to attend all required sessions
Significant health problems that would preclude active participation
Presence of conditions that would make MRI unsafe (e.g. pacemaker) or (e.g. weight and body shape)
Current use of psychoactive medications/drugs as indicated by self-report or urine screen
Trial design
Treatments tested in this trial
- Propranolol
- Nicotine Patch
- Placebo Propranolol
- Placebo Patch
Treatment groups
80 Participants
are divided into 4 treatment groupsSponsors and collaborators
University of Oklahoma
Lead sponsor
Oklahoma State University Center for Health Sciences
Collaborator
Duke University
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator
National Institutes of Health (NIH)
Collaborator
Source ClinicalTrials.gov